

## REFERENCES

1. Hagerman RJ, Ono MY, Hagerman PJ. Recent advances in fragile X: a model for autism and neurodegeneration. *Curr Opin Psychiatry*. 2005 Sep;18(5):490-6.
2. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. *Cell*. 1991;67(6):1047-58.
3. Oberlé I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. *Science*. 1991;252(5010):1097-102.
4. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. *Am J Med Genet*. 1996;64(1):196-7.
5. Faradz SMH, Buckley M, Lam-Po-Tang, Leigh D, Holden JJA. Molecular screening for fragile X syndrome among Indonesian children with developmental disability. *Am J Med Genet*. 1999;83:350-1.
6. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the Fragile-X syndrome. *Am J Hum Genet*. 2000;66(1):6-15.
7. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. *Neurology*. 2001;57(1):127-30.
8. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, et al. Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging Correlates. *Am J Hum Genet*. 2003 Mar 12;72(4):869-78.
9. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, et al. Penetrance of the fragile x-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA*. 2004 Jan 28;291(4):460-9.
10. Jacquemont S, Leehey MA, Hagerman RJ, Beckett LA, Hagerman PJ. Size bias of fragile X premutation alleles in late-onset movement disorders. *J Med Genet*. 2006 May 24;43:804-9.
11. Grigsby J, Brega AG, Jacquemont S, Loesch DZ, Leehey MA, Goodrich GK, et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). *J Neurol Sci*. 2006 Jun 14;248:227-33.
12. Hessler D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. *Am J Med Genet B Neuropsychiatr Genet*. 2005 Sep 23;139B:115-21.

13. Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, et al. Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males: Newly Described Fronto-Subcortical Dementia. *J Clin Psychiatry*. 2006 Jan;67(1):87-94.
14. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). *Brain*. 2006 Dec 5;129(Pt1):243-55.
15. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. *Brain*. 2002;125(Pt 8):1760-71.
16. Galloway JN, Nelson DL. Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. *Future Neurol*. 2009;4(6):785-98.
17. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, Nannen K, et al. Protein composition of the intranuclear inclusions of FXTAS. *Brain*. 2006 Jan;129(Pt 1):256-71.
18. Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated Tremor/Ataxia syndrome (FXTAS). *RNA biology*. 2004;1:103-5.
19. Tassone F, Hagerman RJ, Garcia-Arocena D, Khandjian EW, Greco CM, Hagerman PJ. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. *J Med Genet*. 2004 Apr;41(4):E43.
20. Willemsen R, Oostra BA, Bassell GJ, Dichtenberg J. The fragile X syndrome: From molecular genetics to neurobiology. *Ment Retard Dev Disabil Res Rev*. 2004;10(1):60-7.
21. Hagerman PJ, Hagerman RJ. The Fragile-X Premutation: A Maturing Perspective. *Am J Hum Genet*. 2004 Mar 29;74(5):805-16.
22. Willemsen R, Mientjes E, Oostra BA. FXTAS: A Progressive Neurologic Syndrome Associated with Fragile X Premutation. *Curr Neurol Neurosci Rep*. 2005 Sep;5(5):405-10.
23. Entezam A, Biacsi R, Orrison B, Saha T, Hoffman GE, Grabczyk E, et al. Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. *Gene*. 2007 Mar 16;395:125-34.
24. Bontekoe CJ, Bakker CE, Nieuwenhuizen IM, van Der Linde H, Lans H, de Lange D, et al. Instability of a (CGG)(98) repeat in the Fmr1 promoter. *Hum Mol Genet*. 2001;10(16):1693-9.
25. Van Dam D, Errijgers V, Kooy RF, Willemsen R, Mientjes E, Oostra BA, et al. Cognitive decline, neuromotor and behavioural disturbances in a mouse model for Fragile-X-associated tremor/ataxia syndrome (FXTAS). *Behavioural Brain Research*. 2005;162:233-9.

26. Brouwer JR, Huizer K, Severijnen LA, Hukema RK, Berman RF, Oostra BA, et al. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. *J Neurochem*. 2008 Nov 10;107:1671-82.
27. Brouwer JR, Mientjes EJ, Bakker CE, Nieuwenhuizen IM, Severijnen LA, Van der Linde HC, et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. *Exp Cell Res*. 2007 Oct 13;313:244-53.
28. Berman RF, Willemsen R. Mouse models of fragile X-associated tremor ataxia. *J Investig Med*. 2009;57(8):837-41.
29. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen L, Nieuwenhuizen I, et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. *Hum Mol Genet*. 2003;12(9):949-59.
30. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoter. *Proc Natl Acad Sci* 1992;89:5547-51.
31. Garden GA, Libby RT, Fu YH, Kinoshita Y, Huang J, Possin DE, et al. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. *J Neurosci*. 2002 Jun 15;22(12):4897-905.
32. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A. GFAP promoter directs astrocytes-specific expression in transgenic mice. *J Neurosci*. 1994;14:1030-7.
33. Eichler EE, Richards S, Gibbs RA, Nelson DL. Fine structure of the human FMR1 gene. *Hum Mol Genet*. 1993;2(8):1147-53.
34. Antar LN, Dichtenberg JB, Plociniak M, Afroz R, Bassell GJ. Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. *Genes Brain Behav*. 2005 Aug;4(6):350-9.
35. Hinds HL, Ashley CT, Sutcliffe JS, Nelson DL, Warren ST, Housman DE, et al. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. *Nature Genet*. 1993;3(1):36-43.
36. Kiebler MA, DesGroseillers L. Molecular insights into mRNA transport and local translation in the mammalian nervous system. *Neuron*. 2000;25(1):19-28.
37. Steward O. mRNA at synapses, synaptic plasticity, and memory consolidation. *Neuron*. 2002;36(3):338-40.
38. Dombrowski C, Levesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. *Hum Mol Genet*. 2002;11(4):371-8.

39. Nolin SL, Brown WT, Glicksman A, Houck Jr GE, Gargano AD, Sullivan A, et al. Expansion of the Fragile X CGG Repeat in Females with Premutation or Intermediate Alleles. *Am J Hum Genet.* 2003 Jan 14;72(2):454-64.
40. Reyniers E, Vits L, De Boule K, Van Roy B, Van Velzen D, de Graaff E, et al. The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm. *Nat Genet.* 1993;4(2):143-6.
41. Ludwig AL, Raske C, Tassone F, Arocena DG, Hershey JW, Hagerman PJ. Translation of *FMR1* mRNA is not influenced by AGG interruptions. *Nucleic Acids Research.* 2009;37(20):6896-904.
42. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the FMR1 gene and implications for the population genetics of the fragile X syndrome. *Am J Hum Genet.* 1995;57(5):1006-18.
43. Sherman SL. Premature Ovarian Failure among Fragile X Premutation Carriers: Parent-of-Origin Effect? *Am J Hum Genet.* 2000;67(1):11-3.
44. Allen EG, Juncos J, Letz R, Rusin M, Hamilton D, Novak G, et al. Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test battery. *J Med Genet.* 2008 May;45(5):290-7.
45. Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, et al. Fragile-X-Associated Tremor/Ataxia Syndrome (FXTAS) in Females with the FMR1 Premutation. *Am J Hum Genet.* 2004 Apr 2;74(5):1051-6.
46. Zuhlke C, Budnik A, Gehlken U, Dalski A, Purmann S, Naumann M, et al. FMR1 premutation as a rare cause of late onset ataxia. Evidence for FXTAS in female carriers. *J Neurol.* 2004 Nov;251(11):1418-9.
47. Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. *Ann Neurol.* 2004 Dec 27;57(1):144-7.
48. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. *Curr Opin Genet Dev.* 2002;12(3):278-83.
49. Brunberg JA, Jacquemont S, Hagerman RJ, Berry-Kravis EM, Grigsby J, Leehey MA, et al. Fragile X Premutation Carriers: Characteristic MR Imaging Findings of Adult Male Patients with Progressive Cerebellar and Cognitive Dysfunction. *AJNR Am J Neuroradiol.* 2002;23(10):1757-66.
50. Cohen S, Masyn K, Adams J, Hessel D, Rivera S, Tassone F, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. *Neurology.* 2006 Oct 24;67(8):1426-31.
51. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. *The EMBO Journal.* 2010;29(7):1248-61.

52. Brouwer JR. The Molecular basis of FXTAS. Rotterdam: Erasmus University; 2008.
53. Kenneson A, Zhang F, Hagedorn CH, Warren ST. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. *Hum Mol Genet.* 2001;10(14):1449-54.
54. Tassone F, Hagerman PJ. Expression of the FMR1 gene. *Cytogenet Genome Res.* 2003;100(1-4):124-8.
55. Chen LS, Tassone F, Sahota P, Hagerman PJ. The (CGG)<sub>n</sub> repeat element within the 5'untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. *Hum Mol Genet.* 2003 Sep 30;12:3067-74.
56. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. Reduced FMR1 mRNA translation efficiency in Fragile X patients with premutations. *RNA.* 2002;8:1-7.
57. Ranum LP, Day JW. Pathogenic RNA repeats: an expanding role in genetic disease. *Trends Genet.* 2004 Oct;20(10):506-12.
58. Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, Tassone F, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. *Hum Mol Genet.* 2005 Oct 20;14:3661-71.
59. Handa V, Goldwater D, Stiles D, Cam M, Poy G, Kumari D, et al. Long CGG-repeat tracts are toxic to human cells: Implications for carriers of Fragile X premutation alleles. *FEBS Lett.* 2005 May 9;579(12):2702-8.
60. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, et al. RNA-Mediated Neurodegeneration Caused by the Fragile X Premutation rCGG Repeats in Drosophila. *Neuron.* 2003 Aug 28;39(5):739-47.
61. Hashem V, Galloway JN, Mori M, Willemsen R, Oostra BA, Paylor R, et al. Ectopic expression of CGG containing mRNA is neurotoxic in mammals. *Hum Mol Genet.* 2008;18(13):2443-51.
62. Katsantoni E, Anghelescu N, Rottier R, Moerland M, Antoniou M, de Crom R, et al. Ubiquitous expression of the rtTA2S-M2 inducible system in transgenic mice driven by the human hnRNPA2B1/CBX3 CpG island. *BMC Dev Biol.* 2007;7(108):1471-213X.
63. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell.* 1997 Aug 8;90(3):537-48.
64. Petersen A, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P, et al. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate

- dopamine-mediated striatal neuron autophagy and degeneration. *Hum Mol Genet.* 2001 Jun 1;10(12):1243-54.
65. Koyano S, Iwabuchi K, Yagishita S, Kuroiwa Y, Uchihara T. Paradoxical absence of nuclear inclusion in cerebellar Purkinje cells of hereditary ataxias linked to CAG expansion. *J Neurol Neurosurg Psychiatry.* 2002 Oct;73(4):450-2.
  66. Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. *Ann Neurol.* 2002 Mar;51(3):302-10.
  67. Takahashi J, Fujigasaki H, Zander C, El Hachimi KH, Stevanin G, Durr A, et al. Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content. *Brain.* 2002 Jul;125(Pt 7):1534-43.
  68. Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. *Hum Mol Genet.* 2000;9(15):2321-8.
  69. Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. *Hum Mol Genet.* 2001 May 1;10(10):1049-59.
  70. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. *Science.* 2001 May 25;292(5521):1552-5.
  71. Lukong KE, Richard S. Motor coordination defects in mice deficient for the Sam68 RNA-binding protein. *Behav Brain Res.* 2008 Jun 3;189(2):357-63.
  72. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, et al. Recovery from polyglutamine-induced neurodegeneration in conditional *SCA1* transgenic mice. *The Journal of Neuroscience.* 2004;24(40):8853-61.
  73. Del Río J, Frechilla D. Glutamate and depression. In: Schmidt WJ, Reith MEA, editors. *Dopamine and Glutamate in Psychiatric Disorders: Humana Press; 2005.* p. 215-34.
  74. Kwak S, Weiss JH. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. *Curr Opin Neurobiol.* 2006;16(3):281-7. Epub 2006 May 15.
  75. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. *Proc Natl Acad Sci U S A.* 1993;90(14):6591-5.
  76. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. *Nat Neurosci.* 2006 Oct;9(10):1302-11.

77. Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC, et al. Spectrin mutations cause spinocerebellar ataxia type 5. *Nat Genet.* 2006 Feb;38(2):184-90.
78. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. *J Cell Biol.* 2005 Dec 19;171(6):1001-12.
79. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). *Brain.* 2006;129(Pt 1):243-55. Epub 2005 Dec 5.